Page last updated: 2024-11-13

GRL-0617

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GRL-0617 : A benzamide resulting from the formal condensation of the carboxy group of 5-amino-2-methylbenzoic acid with the amino group of (1R)-1-(naphthalen-1-yl)ethan-1-amine. It is a potent noncovalent inhibitor (IC50 = 600 nM) of severe acute respiratory syndrome-coronavirus papain-like protease (SARS-CoV PLpro). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24941262
CHEMBL ID549695
CHEBI ID167176
SCHEMBL ID1319181

Synonyms (35)

Synonym
grl-0617
CHEBI:167176
5-amino-2-methyl-n-[(1r)-1-(naphthalen-1-yl)ethyl]benzamide
5-amino-2-methyl-n-[(1r)-1-(1-naphthalenyl)ethyl]benzamide
5-amino-2-methyl-n-[(r)-1-(1-naphthyl)ethyl]benzamide
grl0617
AKOS015840255
5-amino-2-methyl-n-[(1r)-1-naphthalen-1-ylethyl]benzamide
1093070-16-6
5-amino-2-methyl-n-(1r-naphthalen-1-yl-ethyl)-benzamide
DB08656
CHEMBL549695
NCGC00188640-01
SCHEMBL1319181
AKOS015924263
S6845
naphthalene and benzamide derivative, 25
bdbm31524
UVERBUNNCOKGNZ-CQSZACIVSA-N
5-amino-2-methyl-n-[2-(naphthalen-1-yl)ethyl]benzamide
DTXSID10660795
compound 25 [pmid: 19645480]
gtpl11078
HY-117043
E73459
Q27097846
EX-A4032
unii-sqh4947ndn
sqh4947ndn ,
benzamide, 5-amino-2-methyl-n-((1r)-1-(1-naphthalenyl)ethyl)-
5-amino-2-methyl-n-((1r)-1-(1-naphthalenyl)ethyl)benzamide
(-)-grl-0617
CS-0063568
BS-48457
AC-36473
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
protease inhibitorA compound which inhibits or antagonizes the biosynthesis or actions of proteases (endopeptidases).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
substituted aniline
benzamides
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1IC50 (µMol)0.60000.03002.72839.5100AID1804127
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)0.60000.00403.43889.5100AID1804127
Transmembrane protease serine 2Homo sapiens (human)IC50 (µMol)0.60000.01802.61989.5100AID1804127
Procathepsin LHomo sapiens (human)IC50 (µMol)0.60000.00021.66619.5100AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusIC50 (µMol)0.60000.03002.29719.5100AID1804127
Replicase polyprotein 1abHuman coronavirus 229EIC50 (µMol)0.60000.03002.14419.5100AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)1.15670.00402.92669.9600AID1799148; AID1801147; AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)2.11910.00022.45859.9600AID1803985; AID1804127; AID1805527; AID1854352; AID1854361; AID1854362; AID1881728; AID1884000; AID1884001; AID1884012; AID1884015; AID1898065
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusIC50 (µMol)0.60000.03002.77319.5100AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)IC50 (µMol)0.60000.00042.207910.0000AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)27.60000.00304.11059.8200AID1803985
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2Kd6.74502.70003.65004.6000AID1805528; AID1884009
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)20.00000.00304.57559.8200AID1805529
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1884012Inhibition of SARS-CoV-2 papain-like protease nsp3 expressed in Escherichia coli BL21 (DE3) using LKGG-AMC probe as substrate by fluorescence based biochemical assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1820443Inhibition of SARS-CoV-2 PLpro assessed as viral PLpro-mediated deISGylation using ISG-15-AMC as substrate at 30 uM preincubated for 10 mins followed by substrate addition measured for 15 mins by fluorescence plate reader assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1884002Antiviral activity against SARS-CoV-2 infected in African green monkey Vero cells assessed as viral growth inhibition incubated for 1 hr by crystal violet staining based plaque reduction assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1820444Inhibition of SARS-CoV-2 PLpro assessed as viral PLpro-mediated inhibition of human USP7-catalysed Ub-AMC hydrolysis using Ub-AMC as substrate at <= 30 uM preincubated for 10 mins followed by substrate addition measured for 15 mins by fluorescence plate r2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1884003Cytotoxicity against African green monkey Vero cells treated for 24 hrs by CCK8 assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1884004Antiviral activity against SARS-CoV-2 infected in African green monkey Vero cells assessed as viral growth inhibition by cell culture based assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1820437Antiviral activity against SARS-CoV-2 infected in African green monkey Vero cells assessed as reduction in virus replication incubated for 66 hrs by Plaque reduction assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1884009Binding affinity to CM5 chip immobilized full-length wild-type SARS-CoV-2 papain-like protease (1564 to 1878 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant incubated for 90 secs by SPR analysis2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID724829Inhibition of SARS-CoV PL-pro by microplate reader analysis2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL pr
AID724828Ratio of EC50 for SARS-CoV infected in african green monkey Vero E6 cells to IC50 for SARS-CoV 3CLpro2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL pr
AID1820441Binding affinity to CMS sensor chip immobilized His-tagged SARS-CoV-2 PLpro assessed as equilibrium dissociation constant by surface plasmon resonance analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1854352Inhibition of SARS-CoV-2 PLpro2022European journal of medicinal chemistry, Oct-05, Volume: 240Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
AID1661019Antiviral activity against SARS coronavirus Urbani infected in monkey Vero E6 cells assessed as reduction in virus-induced cytopathogenicity incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment.
AID1820442Inhibition of SARS-CoV-2 PLpro assessed as viral PLpro-mediated deubiquitination using Ub-AMC as substrate at 30 uM preincubated for 10 mins followed by substrate addition measured for 15 mins by fluorescence plate reader assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1884000Inhibition of full-length SARS-CoV-2 papain-like protease (1564 to 1878 residues) expressed in Escherichia coli Rosetta (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence based multimode plate reader method2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1854362Inhibition of full-length SARS-CoV-2 PLpro expressed in Escherichia coli BL21(DE3) using Ub-Rho as substrate incubated for 5 mins by enzymatic assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
AID725109Antiviral activity against SARS-CoV infected in african green monkey Vero E6 cells at 0.1 to 50 uM after 48 hrs2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL pr
AID1881728Inhibition of SARS CoV-2 PL protease (1541 to 1855 residues) incubated for 3 hrs by microplate reader analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1884001Inhibition of N-terminal 3xFlag-His6-tagged SARS-CoV-2 papain-like protease nsp3 (1564 to 1878 residues) expressed in baculovirus infected Sf9 insect cells using Pro3 as substrate by fluorescence based assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID428667Inhibition of SARS coronavirus PLpro residues 1541-1855 expressed in Escherichia coli2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
AID1881729Antiviral activity against SARS CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by CellTiter-Glo luminescent cell viability assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1884015Inhibition of N-terminal His/TEV-tagged SARS-CoV-2 papain-like protease nsp3 (746 to 1060 residues) expressed in Escherichia coli BL21 (DE3) using (Z-Arg-Leu-Arg-Gly-Gly-AMC as substrate measured for 3 mins by multilabel plate reader method2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1820447Antiviral activity against SARS-COV-2 USA/WA1/2020 in human A549 cells overexpressing ACE2 receptor assessed as reduction in viral replication at MOI of 0.01 pretreated for 1 hr followed by viral infection and further incubated for 1 hr measured after 48 2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1854360Antiviral activity against SARS-CoV-2 infected in human Caco-2 cells expressing hACE2 assessed as reduction in virus replication2022European journal of medicinal chemistry, Oct-05, Volume: 240Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
AID1898065Inhibition of SARS-CoV-2 PLpro2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
AID1854361Inhibition of full-length SARS-CoV-2 PLpro expressed in Escherichia coli BL21(DE3) using HCC-RLRGG-NH(CH2)4NH-DABCYL probe as substrate incubated for 30 mins by enzymatic assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
AID1815327Inhibition of SARS CoV-2 papain-like protease using Z-Arg-Leu-Arg-Gly-Gly-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 50 mins by multimode plate reader method2021European journal of medicinal chemistry, Dec-15, Volume: 226Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
AID1820436Antiviral activity against SARS-CoV infected in African green monkey Vero cells assessed as inhibition of viral replication2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1820440Inhibition of SARS-CoV-2 PLpro using Z-RLRGG-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 15 mins by fluorescence plate reader assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID428668Antiviral activity against SARS coronavirus in african green monkey Vero E6 cells assessed as inhibition of replication after 48 hrs2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
AID1881730Antiviral activity against SARS CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation incubated for 72 hr by plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1803985Inhibition of SARS-CoV-2 PLpro by SARS-CoV PLpro Inhibitors from Article 10.1021/acsinfecdis.0c00168: \\Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.\\2020ACS infectious diseases, 08-14, Volume: 6, Issue:8
Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
AID1799148SARS-CoV PLpro Enzyme Inhibition Assay from Article 10.1021/jm900611t: \\Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease.2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
AID1805527PLpro Primary Assay from Article 10.1021/acs.jmedchem.1c01307: \\Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.\\2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1805528Secondary Binding Analysis by Surface Plasmon Resonance from Article 10.1021/acs.jmedchem.1c01307: \\Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.\\2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1801147Fluorimetric Assay from Article 10.1021/cb500917m: \\Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.\\2015ACS chemical biology, Jun-19, Volume: 10, Issue:6
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
AID1805529Antiviral Activity Assay from Article 10.1021/acs.jmedchem.1c01307: \\Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.\\2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's2 (15.38)24.3611
2020's10 (76.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.63 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index29.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (30.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (69.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]